Asset Details
Do you wish to reserve the book?
Impact of adjuvant chemotherapy on survival in ypT0-2 N0 rectal cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of adjuvant chemotherapy on survival in ypT0-2 N0 rectal cancer
Do you wish to request the book?
Impact of adjuvant chemotherapy on survival in ypT0-2 N0 rectal cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of adjuvant chemotherapy on survival in ypT0-2 N0 rectal cancer
2025
Overview
Purpose
The role of adjuvant chemotherapy in rectal cancer patients downstaged to ypT0-2 N0 after neoadjuvant chemoradiotherapy (CRT), and surgery is still debated. This study investigates the impact of adjuvant chemotherapy on survival outcomes in this patient population.
Methods
This retrospective study analyzed hospital records of rectal cancer cases from Shefa Al Orman Cancer Hospital between January 2016 and December 2020, focusing on patients downstaged to ypT0-2 N0 after neoadjuvant CRT and surgery. Patients were divided into two groups based on whether they received adjuvant chemotherapy. Baseline characteristics, DFS, and OS were compared, and survival factors were analyzed using univariate and multivariate Cox regression.
Results
Eighty-five patients met the inclusion criteria; 55 received adjuvant chemotherapy, and 30 did not. The median age was 52, but those receiving adjuvant therapy were younger (47 vs. 60 years,
P
= 0.006). No significant differences were observed in sex, tumor location, or pathology between groups. Although adjuvant chemotherapy showed a trend toward better 3-year DFS (89.5% vs. 81.9%,
P
= 0.153) and OS (88.1% vs. 84.6%,
P
= 0.654), these differences were not statistically significant. Univariate and multivariate analyses confirmed no significant effect of adjuvant chemotherapy on DFS or OS, nor were any other variables significantly associated with survival.
Conclusion
Adjuvant chemotherapy did not significantly improve DFS or OS in rectal cancer patients downstaged to ypT0-2 N0 following neoadjuvant CRT and surgery. Further studies are needed to define the role of adjuvant therapy in this group.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Antigens
/ Cancer
/ Female
/ Humans
/ Male
/ Medicine
/ Patients
/ Rectal Neoplasms - drug therapy
/ Rectal Neoplasms - mortality
/ Rectal Neoplasms - pathology
/ Rectum
/ Surgery
/ Survival
